Lyon - Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases, announces the creation and funding of a new joint public / private laboratory in collaboration with BIORAN, a team from the Lyon Neuroscience Research Center (CRNL) and CERMEP, the regional biomedical imaging platform dedicated to clinical and basic research.

This 'NeuroImaging for Drug Discovery (NI2D)' laboratory aims to strengthen the understanding of the cellular and molecular mechanisms of drug candidates developed by the company Theranexus and more particularly at the level of neurons and astrocytes - using new tools of preclinical neuroimaging.

'The approach developed by Theranexus requires the development of new tools for neuroimaging and we are happy to perpetuate our collaboration, already successful with this company, as part of our joint laboratory NI2D' says the Professor Luc Zimmer, Director and CERMEP from the BIORAN team at the Lyon Neuroscience Research Center.

'We are very happy to be able to create a joint laboratory with the research teams at the forefront of innovation in neuroimaging from BIORAN and CERMEP and we would like to thank the ANR for its funding. This laboratory will be dedicated to a better understanding of the neuron-glial cell mechanisms of Theranexus drug candidates 'concludes Franck Mouthon, Chairman and CEO and co-founder of Theranexus.

This project is supported by funding of almost EUR 350,000 by the National Research Agency, which is in addition to the funding of EUR 200,000 already obtained from the Auvergne-Rhone-Alpes Region 1. The two partners actively contribute by making personnel and equipment available.

About the Lyon Neuroscience Research Center (CRNL; supervisory authorities: Universite Claude Bernard Lyon 1, INSERM, CNRS).

The CRNL brings together the expertise of 18 teams whose common objective is to develop multidisciplinary research aimed at understanding the complexity of brain functioning as well as certain dysfunctions linked to neurological or psychiatric pathologies.

Within the CRNL, the BIORAN team (Radiopharmaceutical and Neurochemical Biomarkers) brings together expertise in neurochemistry, neuropharmacology and neuroimaging with the aim of inventing new probes and new imaging protocols for the exploration of the biochemistry of the brain in the context of diagnosis and treatment.

ABOUT THERANEXUS

Founded in 2013, THERANEXUS is a clinical stage biopharmaceutical company from CEA that develops drug candidates for the treatment of diseases of the nervous system. THERANEXUS has identified the major role of non-neuronal cells (otherwise called 'glial cells') in the response to psychotropic drugs (targeting neurons). The company is a pioneer in the design and development of drug candidates acting on the interaction between neurons and glial cells. The unique and patented technology exploited by THERANEXUS aims to increase the effectiveness of psychotropic drugs already approved and marketed by combining them with a glial cell modulator.

Proprietary and adaptable, the THERANEXUS platform makes it possible to generate various proprietary drug candidates with high added value in several indications.

Contact

Tel: 33 (0) 6 07 76 82 83

Email: fportejoie@fp2com.fr

(C) 2020 Electronic News Publishing, source ENP Newswire